A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
- Mayo Clinic, United States
- University of Wisconsin-Madison, United States
- University of California, Davis, United States
- University of California, Irvine, United States
- University of Maryland, Baltimore, United States
- The University of Texas Health Science Center at Houston, United States
- Qingdao University, China
- Shanghai Jiao Tong University, China
Abstract
Previously we showed the generation of a protein trap library made with the gene-break transposon (GBT) in zebrafish (Danio rerio) that could be used to facilitate novel functional genome annotation towards understanding molecular underpinnings of human diseases (Ichino et al, 2020). Here, we report a significant application of this library for discovering essential genes for heart rhythm disorders such as sick sinus syndrome (SSS). SSS is a group of heart rhythm disorders caused by malfunction of the sinus node, the heart's primary pacemaker. Partially owing to its aging-associated phenotypic manifestation and low expressivity, molecular mechanisms of SSS remain difficult to decipher. From 609 GBT lines screened, we generated a collection of 35 zebrafish insertional cardiac (ZIC) mutants in which each mutant traps a gene with cardiac expression. We further employed electrocardiographic measurements to screen these 35 ZIC lines and identified three GBT mutants with SSS-like phenotypes. More detailed functional studies on one of the arrhythmogenic mutants, GBT411, in both zebrafish and mouse models unveiled Dnajb6 as a novel SSS causative gene with a unique expression pattern within the subpopulation of sinus node pacemaker cardiomyocytes that partially overlaps with the expression of hyperpolarization activated cyclic nucleotide gated channel 4 (Hcn4), supporting heterogeneity of the cardiac pacemaker cells.
Data availability
All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figure 4 and Figure 7.
Article and author information
Author details
Funding
Mayo Foundation for Medical Education and Research
- Xiaolei Xu
Wisconsin Partnership Program 4140
- Alexey V Glukhov
American Heart Association (17POST33370089)
- Di Lang
American Heart Association (846898)
- Di Lang
National Institute of Health (R00HL138160)
- Stefano Morotti
National Institute of Health (1OT2OD026580-01)
- Eleonora Grandi
Science and Technology Innovation Action Plan of Shanghai (201409005600)
- Yigang Li
National Institute of Health (GM063904)
- Stephen C Ekker
American Heart Association (16SDG29120011)
- Alexey V Glukhov
National Institute of Health (R00HL138160)
- Stefano Morotti
National Institute of Health (R01HL131517,P01HL141084)
- Eleonora Grandi
American Heart Association (15SDG24910015)
- Eleonora Grandi
American Heart Association (20POST35120462)
- Haibo Ni
National Institute of Health (NIH R01HL141214)
- Alexey V Glukhov
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All experiments were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication No. 85-23, revised 1996). All animal procedures and protocols used in these studies (for zebrafish, #: A00005409-20; for mouse, #: A00003511-20 and M005490-R02) have been approved by the Mayo Clinic Institutional Animal Care and Use Committee (Permit number: D16-00187) and by the Animal Care and Use Committee of University of Wisconsin-Madison (Permit number: D16-00239).
Copyright
© 2022, Ding et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 947
- views
-
- 189
- downloads
-
- 7
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
eLife 11:e77327.
https://doi.org/10.7554/eLife.77327
Further reading
-
- Epidemiology and Global Health
- Genetics and Genomics
Burden of stroke differs by region, which could be attributed to differences in comorbid conditions and ethnicity. Genomewide variation acts as a proxy marker for ethnicity, and comorbid conditions. We present an integrated approach to understand this variation by considering prevalence and mortality rates of stroke and its comorbid risk for 204 countries from 2009 to 2019, and Genome-wide association studies (GWAS) risk variant for all these conditions. Global and regional trend analysis of rates using linear regression, correlation, and proportion analysis, signifies ethnogeographic differences. Interestingly, the comorbid conditions that act as risk drivers for stroke differed by regions, with more of metabolic risk in America and Europe, in contrast to high systolic blood pressure in Asian and African regions. GWAS risk loci of stroke and its comorbid conditions indicate distinct population stratification for each of these conditions, signifying for population-specific risk. Unique and shared genetic risk variants for stroke, and its comorbid and followed up with ethnic-specific variation can help in determining regional risk drivers for stroke. Unique ethnic-specific risk variants and their distinct patterns of linkage disequilibrium further uncover the drivers for phenotypic variation. Therefore, identifying population- and comorbidity-specific risk variants might help in defining the threshold for risk, and aid in developing population-specific prevention strategies for stroke.
-
- Genetics and Genomics
Familial exudative vitreoretinopathy (FEVR) is a severe genetic disorder characterized by incomplete vascularization of the peripheral retina and associated symptoms that can lead to vision loss. However, the underlying genetic causes of approximately 50% of FEVR cases remain unknown. Here, we report two heterozygous variants in calcyphosine-like gene (CAPSL) that is associated with FEVR. Both variants exhibited compromised CAPSL protein expression. Vascular endothelial cell (EC)-specific inactivation of Capsl resulted in delayed radial/vertical vascular progression, compromised endothelial proliferation/migration, recapitulating the human FEVR phenotypes. CAPSL-depleted human retinal microvascular endothelial cells (HRECs) exhibited impaired tube formation, decreased cell proliferation, disrupted cell polarity establishment, and filopodia/lamellipodia formation, as well as disrupted collective cell migration. Transcriptomic and proteomic profiling revealed that CAPSL abolition inhibited the MYC signaling axis, in which the expression of core MYC targeted genes were profoundly decreased. Furthermore, a combined analysis of CAPSL-depleted HRECs and c-MYC-depleted human umbilical vein endothelial cells uncovered similar transcription patterns. Collectively, this study reports a novel FEVR-associated candidate gene, CAPSL, which provides valuable information for genetic counseling of FEVR. This study also reveals that compromised CAPSL function may cause FEVR through MYC axis, shedding light on the potential involvement of MYC signaling in the pathogenesis of FEVR.
